Veru Pharmaceuticals Inc.’s COVID-19 therapy VERU-111 (sabizabulin) failed to win full support from the U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee, which was asked to decide about endorsing the firm’s request for an emergency use authorization to market the drug.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Acelyrin, Achieve, Adaptimmune, Alnylam, Amgen, Arrowhead, Astrazeneca, Bicycle, Biosenic, Bridge, Cincor, Dermavant, Galecto, Horizon, Idorsia, Inmagene, Intercept, Ionis, ISA, Janssen, Medincell, Milestone, Mirum, NLS, Novartis, Novavax, Nycode, Onquality, Poxel, Rhythm, Sirnaomics, Vaxxas, Xencor.

Briefing documents related to the Nov. 9 meeting of the U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee augur well for Veru Pharmaceuticals Inc.’s request for an emergency use authorization to market VERU-111 (sabizabulin) as a treatment for COVID-19.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brexogen, Inhibikase, Moderna, Sensorion, Sinovac, Verve.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astellas, Avenue, Baergic, Bioarctic, CNBX, Fairwinds, Famygen, Fibrogen, Fortress, Fulgent Genetics, Fulgent Pharma, GSK, Merck & Co., MGFB, Nrx, Onethree, Ocuphire, Pfizer, Poolbeg, Portage, Precisionlife, Relief, Salipro, Sanofi, Sosei, Spanios, Spero, Tageza, Unravel.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apellis, Astrazeneca, Iveric, Medincell, Moderna, Sanofi, Teva.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akeso, Ascentage, Bioatla, Biomind, Biontech, Laurent, NGM, Pfizer, Rain, Redhill, Vicore.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aim Immunotech, Antengene, Ascletis, Beigene, Brexogen, Codagenix, Creative Medical, Crispr, Decibel, Eccogene, Eisai, Gilead, NLS, Omega, Pfizer, Pharmala, Sernova.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Cynata, Kinarus.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Abeona, Actinium, Aelix, Albireo, Apeiron, Aramis, Arbutus, Ardelyx, Atea, Biontech, Biophytis, Blaze, Chinook, Clairvoyant, Compass, Daewoong, Emergent, G1, GSK, Inozyme, Lianbio, Madrigal, Neurocrine, Neurotech, Ose, Pfizer, Regenxbio, Regulus, Renovion, Rhythm, Rigel, Sagimet, Sonnet, Surface Oncology, Syndax, Theriva, Transgene, Uniqure, Vectivbio.